This report provides a comprehensive overview of global oncology trends, including cancer incidence, treatment innovation, spending, and access. Oncology remains the largest area of pharmaceutical R&D investment, with strong growth in targeted therapies, immunotherapies, and biomarker-driven treatments. The report highlights increasing treatment complexity, longer therapy durations, and rising costs, alongside persistent disparities in access between countries and regions. While innovation continues at pace, many health systems struggle with affordability, infrastructure readiness, and reimbursement delays. The analysis emphasizes the need for sustainable financing models, earlier diagnosis, and coordinated policy efforts to ensure patients benefit from continued oncology innovation.

Join for free to read